A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Systemic scleroderma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FASST
  • Sponsors Inventiva Pharma
  • Most Recent Events

    • 20 Jun 2018 According to an Inventiva Pharma media release, the Data Safety Monitoring Board (DSMB) held the third and last meeting for this trial and recommended that the study should continue without any modification to the protocol.
    • 15 May 2018 According to an Inventiva Pharma media release, Of the 145 randomized patients enrolled into the trial, 120 patients have been treated for six months, including 80 patients that have already completed the one-year treatment.
    • 04 Jan 2018 According to an Inventiva Pharma media release, Of the 145 randomized patients 100 patients have been treated for 6 months including 54 patients that have already completed the one year treatment, and topline results are anticipated in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top